Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 7-12

  Vadhan Raj, Saroj ^a   Strauss, William ^b   Ford, David ^c   Bernard, Kristine ^b   Boccia, Ralph ^d   Li, Joe ^b   Allen, Lee F ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMAG PHARMACEUTICALS INC   (United States)

^c Toronto Digestive Disease Associates   (Canada)

^d Center for Cancer and Blood Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERUMOXYTOL; HEMOGLOBIN; IRON; PLACEBO;

ANAPHYLAXIS; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE SCORE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; FERROSOFERRIC OXIDE; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892882355     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23582     Document Type: Article

References (37)

1. Bergamaschi G, Markopoulos K, Albertini R, et al. Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. Haematologica 2008;93:1785-1791.
2. World Health Organization. Worldwide prevalence of anaemia 1995-2005: WHO global database on anaemia. Geneva, Switzerland: World Health Organization; 2008. pp 1-40.
3. Niv E, Elis A, Zissin R, et al. Iron deficiency anemia in patients without gastrointestinal symptoms-A prospective study. Fam Pract 2005;22:58-61.
4. Croker JR, Beynon G. Gastro-intestinal bleeding-A major cause of iron deficiency in the elderly. Age Ageing 1981;10:40-43.
5. Liu K, Kaffes AJ. Iron deficiency anaemia: A review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 2012;24:109-116.
6. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:513-519.
7. Tsiolakidou G, Koutroubakis IE. Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World J Gastroenterol 2007;13:4798-4806.
8. Patterson AJ, Brown WJ, Powers JR, Roberts DC. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women's Health. Qual Life Res 2000;9:491-497.
9. Hinton PS, Giordano C, Brownlie T, Haas JD. Iron supplementation improves endurance after training in iron-depleted, nonanemic women. J Appl Physiol 2000;88:1103-1111.
10. Haas JD, Brownlie Tt. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J Nutr 2001;131:676S-688S; discussion 688S-690S.
11. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004;53:1190-1197.
12. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000;109:27-32.
13. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 2004;15:979-986.
14. Diez-Lobo AI. Preoperative intravenous iron administration corrects anemia and reduces transfusion requirement in women undergoing abdominal hysterectomy. Trans Alt Trans Med 2007;9:114-119.
15. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-1192.
16. Stoltzfus RJ. Iron-deficiency anemia: Reexamining the nature and magnitude of the public health problem. Summary: Implications for research and programs. J Nutr 2001;131:697S-700S; discussion 700S-701S.
17. Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-393.
18. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anaemia of chronic disease: A review and strategic recommendations. Curr Med Res Opin 2006;22:731-737.
19. Dexferrum [package insert]. Shirley, NY: American Regent Laboratories, Inc.; 2009.
20. INFed Prescribing Information. Morristown, NY: Watson Pharma, Inc.; 2009.
21. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med 2007;357:93-94.
22. McCormack PL. Ferumoxytol: In iron deficiency anaemia in adults with chronic kidney disease. Drugs 2012;72:2013-2022.
23. Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011;4:399-406.
24. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
25. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575.
26. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010;85:650-654.
27. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011;86:860-862.
28. MacDougall IC, McGlaughlin J, Fortin GS, et al. FIRST: Head-to-head comparison study (Ferumoxytol compared to IRon Sucrose Trial) of the safety and efficacy of ferumoxytol with iron sucrose for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Presented at the American Society of Nephrology 44th annual meeting 2011, Philadelphia, PA, USA, 2011.
29. Rawal A, Katsulis P, Stutz L, et al. Comparison of intravenous iron therapy for the treatment of anemia in CKD. Presented at the National Kidney Foundation Spring Meeting (SCM13) 2013, Orlando, FL, USA, 2013.
30. Meyers M, Erdal E, Khan C, et al. Efficiency outcomes associated with increased ferumoxytol use in an infusion clinic. Presented at the American Society of Health System Pharmacists Midyear Clinical Meeting 2011, New Orleans, LA, USA. Poster No. 5-004. 2011.
31. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
32. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-345.
33. Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality scale: Using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 2007;23:731-739.
34. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
35. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-1605.
36. Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005;68:1801-1807.
37. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008;52:907-915.